AU2002212505A1 - Dna expression vectors - Google Patents
Dna expression vectorsInfo
- Publication number
- AU2002212505A1 AU2002212505A1 AU2002212505A AU1250502A AU2002212505A1 AU 2002212505 A1 AU2002212505 A1 AU 2002212505A1 AU 2002212505 A AU2002212505 A AU 2002212505A AU 1250502 A AU1250502 A AU 1250502A AU 2002212505 A1 AU2002212505 A1 AU 2002212505A1
- Authority
- AU
- Australia
- Prior art keywords
- expression vectors
- dna expression
- vectors
- host cells
- intron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013604 expression vector Substances 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
- 108700002232 Immediate-Early Genes Proteins 0.000 abstract 1
- 229940065638 intron a Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Abstract
The invention relates to DNA vectors containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A. Vectors, host cells, pharmaceutical and vaccine compositions comprising such host cells and vectors are contemplated.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0027088.4 | 2000-11-06 | ||
GBGB0027088.4A GB0027088D0 (en) | 2000-11-06 | 2000-11-06 | DNA expression vectors |
PCT/GB2001/004912 WO2002036792A2 (en) | 2000-11-06 | 2001-11-02 | Dna expression vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002212505A1 true AU2002212505A1 (en) | 2002-05-15 |
Family
ID=9902639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002212505A Abandoned AU2002212505A1 (en) | 2000-11-06 | 2001-11-02 | Dna expression vectors |
Country Status (10)
Country | Link |
---|---|
US (2) | US20040082531A1 (en) |
EP (1) | EP1334201B1 (en) |
JP (1) | JP2004512837A (en) |
AT (1) | ATE473283T1 (en) |
AU (1) | AU2002212505A1 (en) |
CA (1) | CA2427952A1 (en) |
DE (1) | DE60142519D1 (en) |
ES (1) | ES2346850T3 (en) |
GB (1) | GB0027088D0 (en) |
WO (1) | WO2002036792A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003263150A1 (en) * | 2002-09-12 | 2004-04-30 | Pharmexa A/S | Immunization against autologous ghrelin |
GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
US20040146486A1 (en) * | 2003-01-24 | 2004-07-29 | Juan Sun | Hybrid vector system for use as a vaccine |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
NZ546554A (en) * | 2003-10-10 | 2009-04-30 | Powderject Vaccines Inc | Nucleic acid constructs |
GB0400965D0 (en) * | 2004-01-16 | 2004-02-18 | Glaxo Group Ltd | Promoter |
US7785875B2 (en) * | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
WO2006026394A2 (en) * | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Method of eliciting an immune response against hiv |
EP1786450A4 (en) * | 2004-08-27 | 2009-11-11 | 3M Innovative Properties Co | Hiv immunostimulatory compositions |
US7429480B2 (en) * | 2005-01-10 | 2008-09-30 | National Taiwan University | Promoter sequences from WSSV immediate early genes and their uses in recombinant DNA techniques |
JP2008527001A (en) * | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | Prostate stem cell antigen vaccine and uses thereof |
GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
EP2368986A1 (en) * | 2005-09-08 | 2011-09-28 | The Research Foundation For Microbial Diseases Of Osaka University | Promoter for introducing gene into lymphocyte or blood cell and application thereof |
NZ574239A (en) | 2006-07-18 | 2011-12-22 | Glaxosmithkline Biolog Sa | Hybrid fusion proteins for malaria vaccines |
CL2007003743A1 (en) | 2006-12-22 | 2008-07-11 | Bayer Cropscience Ag | COMPOSITION THAT INCLUDES FENAMIDONA AND AN INSECTICIDE COMPOUND; AND METHOD TO CONTROL FITOPATOGENOS CULTURES AND INSECTS FACING OR PREVENTIVELY. |
BRPI0808553A2 (en) | 2007-03-02 | 2014-08-19 | Glaxosmithkline Biolog Sa | METHODS FOR INCREASING AN IMMUNE RESPONSE AGAINST A PATHOGEN, ESTIMATE THE PRODUCTION OF CD4 + AND / OR CD8 + T CELLS AND / OR SPECIFIC PATHOGEN ANTIBODIES AND FOR STIMULATING AN IMMUNE RESPONSE IN A COMPOSED MAMMIN, , KIT |
GB0710538D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Vaccine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
FR2735789B1 (en) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | RECOMBINANT ADENOVIRUSES, THEIR USE FOR PREPARING AVA, COMPLEMENTARY CELL LINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
KR20000006334A (en) * | 1998-06-26 | 2000-01-25 | 이선경 | High efficiency retroviral vectors that contain none of viral coding sequences |
CA2425852C (en) * | 2000-10-13 | 2009-09-29 | Chiron Corporation | Cytomegalovirus intron a fragments |
-
2000
- 2000-11-06 GB GBGB0027088.4A patent/GB0027088D0/en not_active Ceased
-
2001
- 2001-11-02 DE DE60142519T patent/DE60142519D1/en not_active Expired - Lifetime
- 2001-11-02 US US10/415,999 patent/US20040082531A1/en not_active Abandoned
- 2001-11-02 AU AU2002212505A patent/AU2002212505A1/en not_active Abandoned
- 2001-11-02 ES ES01980716T patent/ES2346850T3/en not_active Expired - Lifetime
- 2001-11-02 JP JP2002539538A patent/JP2004512837A/en active Pending
- 2001-11-02 WO PCT/GB2001/004912 patent/WO2002036792A2/en active Application Filing
- 2001-11-02 AT AT01980716T patent/ATE473283T1/en not_active IP Right Cessation
- 2001-11-02 CA CA002427952A patent/CA2427952A1/en not_active Abandoned
- 2001-11-02 EP EP01980716A patent/EP1334201B1/en not_active Expired - Lifetime
-
2007
- 2007-03-07 US US11/683,194 patent/US20090130126A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60142519D1 (en) | 2010-08-19 |
WO2002036792A3 (en) | 2002-09-06 |
GB0027088D0 (en) | 2000-12-20 |
JP2004512837A (en) | 2004-04-30 |
WO2002036792A2 (en) | 2002-05-10 |
EP1334201A2 (en) | 2003-08-13 |
CA2427952A1 (en) | 2002-05-10 |
ATE473283T1 (en) | 2010-07-15 |
US20090130126A1 (en) | 2009-05-21 |
ES2346850T3 (en) | 2010-10-21 |
EP1334201B1 (en) | 2010-07-07 |
US20040082531A1 (en) | 2004-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002212505A1 (en) | Dna expression vectors | |
ZA988585B (en) | Pharmaceutical compositions containing plasma protein. | |
AU2002211710A1 (en) | Cytomegalovirus intron a fragments | |
AU2002230691A1 (en) | Putrescine-n-methyltransferase promoter | |
WO2000017233A3 (en) | Genes of the 1-desoxy-d-xylulose biosynthetic pathway | |
DK1025236T3 (en) | Human checkpoint kinase, HCDS1, preparations and methods | |
AU2002325683A1 (en) | Recombinant vector derived from adeno-associated virus for gene therapy | |
WO2002022835A3 (en) | Targeted genetic manipulation using mu bacteriophage cleaved donor complex | |
MXPA02003232A (en) | Compositions and methods for altering gene expression. | |
ZA200106413B (en) | T Helper cell epitopes. | |
AU2003234198A1 (en) | Novel genes, compositions, and methods for modulating the unfolded protein response | |
MX9806041A (en) | PURIFIED SR-p70 PROTEIN. | |
AU2003285346A1 (en) | Regulatory elements in the 5' region of the vr1 gene | |
AU7216498A (en) | Inhibitors of the urokinase receptor | |
WO2000052045A3 (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
WO1999022005A3 (en) | Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor | |
AU3556800A (en) | Expression of dna or proteins in (c. elegans) | |
WO1999012945A3 (en) | Hydrophobic glycosylamine derivatives, compositions, and methods for use | |
AU2002340898A1 (en) | Design of artificial genes for use as controls in gene expression analysis systems | |
AU2003227622A1 (en) | Methylthiophene carboxanilides | |
IL151211A0 (en) | Compositions useful for regulating parkin gene activity | |
AU2003233849A8 (en) | Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof | |
WO2002066013A3 (en) | Liposome-mediated dna administration | |
EP0962533A3 (en) | Sugar-responsive enhancers in alpha-amylase genes | |
AU5920799A (en) | Genes from human chromosome 11p15.5 |